BBIO
BridgeBio Pharma, Inc. · NASDAQ
- Sector Health Technology
- Industry Biotechnology
- Website bridgebio.com
- Employees(FY) 392
- ISIN US10806X1028
Performance
+4.73%
1W
+19.22%
1M
-19.13%
3M
+4.26%
6M
-25.46%
YTD
+113.71%
1Y
Profile
BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include AG10 and BBP-265, a small molecule stabilizer of transthyretin, or TTR that is in Phase 3 clinical trial for the treatment of TTR amyloidosis-cardiomyopathy, or ATTR-CM; BBP-831, a small molecule selective FGFR1-3 inhibitor, which is Phase 2 clinical trial to treat achondroplasia in pediatric patients; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 2 proof-of-concept clinical trial for Autosomal Dominant Hypocalcemia Type 1, or ADH1; and BBP-711 for the treatment of hyperoxaluria, as well as patients suffering from recurrent kidney stones. In addition, it engages in developing products for Mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and The Regents of the University of California; Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.
Investment Analysis Report: BBIO
Overview
BBIO is a biotechnology company operating in the Health Technology sector. The company has shown significant growth in market capitalization over the years, indicating investor interest in its potential. In this report, we will analyze BBIO's financial health, earnings and revenue growth, profitability, ...
Technical Analysis of BBIO 2024-05-10
Overview:
In analyzing the technical indicators for BBIO over the last 5 days, we will delve into the trend, momentum, volatility, and volume indicators to provide a comprehensive outlook on the possible stock price movement. By examining these key aspects, we aim to offer valuable insights and predictions for the upcoming days.
Trend Analysis:
...Recent News & Updates
- 2024-05-15 07:30
- 2024-05-14 19:30
- 2024-05-14 07:30
- 2024-05-13 19:30
- 2024-05-13 07:30
- 2024-05-12 19:30
- 2024-05-04 09:26
- 2024-05-03 06:44
BridgeBio Pharma First Quarter 2024 Earnings: Beats Expectations(Simply Wall St.)
- 2024-05-03 06:22
BridgeBio Oncology Therapeutics launches with $200m funding(Pharmaceutical Technology)
- 2024-05-02 10:55
- 2024-05-02 10:27
- 2024-05-02 07:40
BridgeBio Pharma: Q1 Earnings Snapshot(Associated Press Finance)
- 2024-05-02 07:30
- 2024-05-02 07:00
- 2024-05-02 03:00
BridgeBio spinout launches with $200M for KRAS cancer drugs(BioPharma Dive)
- 2024-05-01 19:30
- 2024-05-01 19:00
- 2024-05-01 08:10
- 2024-04-25 10:02
- 2024-04-24 22:02
- 2024-04-10 07:30
- 2024-04-09 19:30
- 2024-04-07 13:15
- 2024-04-07 01:15
- 2024-03-27 09:25
- 2024-03-20 07:30
- 2024-03-19 19:30
- 2024-03-05 23:53
- 2024-03-05 12:58
- 2024-03-05 10:53
Page 1 of 6
previousnext